The greater use of biosimilars may have the potential to help reduce drug costs. However, biosimilars have yet to gain traction in the US. In 2010, Congress created an abbreviated licensure pathway for biosimilars, but it is unclear whether and how health plans prioritize coverage of these products. We examined how commercial health plans cover biosimilars relative to reference products.
